In fully murine (syngeneic) models of CAR-CD19 therapy of B cell malignancy, control of tumor cell outgrowth over time and in the context of leukemic rechallenge required the presence of normal B cells [51, 52]. The gene discussed is CD19; the disease is neoplasm.